ProFound Therapeutics and Gates Foundation Announce $35 Million Target Discovery Partnership for Preeclampsia
$35 Million Non-Dilutive Target Discovery Agreement
ProFound Therapeutics, a company under Flagship Pioneering, has entered into a collaboration with the Gates Foundation to identify new biomarkers and therapeutic targets for preeclampsia, with a potential total value of up to $35 million. ProFound will receive an initial payment of $20 million and an additional $15 million upon achieving experimental milestones, with no equity investment or royalty terms included in the announcement. The non-dilutive funding secured at the target discovery stage before candidate drug development highlights the platform's industrial validation and risk mitigation in biopharma.
Dark Proteome and Placental Tissue Analysis
ProFound will leverage its database of dark proteome proteins—those difficult to capture with traditional proteomic methods—to compare normal and preeclamptic placental tissues. The company plans to use agentic AI to predict the functions of candidate proteins and validate them experimentally. The research is still in the preclinical stage, with no named drugs or clinical candidates yet. This approach focuses on identifying novel disease-causing proteins rather than optimizing existing targets in poorly understood pathophysiologies, which could lead to both diagnostic biomarkers and therapeutic applications if successful.
Treatment Standards and Regulatory Gaps
Currently, there are no FDA- or EMA-approved therapies that address the root cause of preeclampsia, and delivery remains the only definitive solution. Clinically, labetalol (Trandate, alpha1 and beta-adrenergic receptor blocker), nifedipine (Procardia, L-type calcium channel blocker), and hydralazine are used to lower blood pressure, while magnesium sulfate (central nervous system excitability inhibitor) is used to prevent seizures. FDA has approved magnesium sulfate for seizure prevention and control in eclampsia, but no therapies have been approved to modify the disease or safely extend pregnancy, and no relevant AdComm votes are mentioned in this partnership.
Competitive Pipeline and Market Potential
The most direct competitor is Comanche Biopharma's CBP-4888, an siRNA that inhibits soluble fms-like tyrosine kinase 1 (sFlt-1), currently in Phase 1 trial NCT07282171 with up to 60 pregnant participants. DiaMedica Therapeutics (DMAC) is in Phase 2 with DM199, a recombinant human tissue kallikrein-1 (rhKLK1), and Health Canada approved its early-onset preeclampsia trial in March 2026. The global preeclampsia market was valued at $736.7 million in 2025 and is projected to reach $887.7 million by 2036. ProFound's long-term value will depend on its ability to convert disease-modifying targets into actual drug candidates.
Strategic Implications of Platform Expansion
Since its 2022 launch, ProFound has established research collaborations with Novartis (NVS), Pfizer (PFE), and GSK (GSK), with its pipeline focused on oncology. This partnership expands its pharma-centric collaborations into women's health and global health, aligning with the Gates Foundation's commitment to invest $2.5 billion in women's health R&D by 2030. In the short term, cash inflow and placental data accumulation are key, while mid-to-long-term value will hinge on whether validated targets can be transitioned into new drug development or licensing agreements.
The structure of receiving $20 million upfront and up to an additional $15 million at the target discovery stage, with no drug candidates yet identified, represents strong external validation of ProFound Therapeutics' dark proteome platform. For researchers, it provides a large-scale data foundation to simultaneously discover causal proteins and biomarkers for preeclampsia by combining placental tissue and agentic AI. The 2025 market size of $736.7 million and the absence of disease-modifying approvals support commercial opportunity, but Comanche Biopharma's sFlt-1 siRNA CBP-4888 in Phase 1 and DiaMedica Therapeutics (DMAC)'s KLK1 protein DM199 in Phase 2 are ahead in clinical development, creating a significant gap. Short-term impact includes non-dilutive research funding and platform expansion, while mid-to-long-term success depends on whether discovered targets pass reproducibility and pregnancy safety validation to transition into drug candidates and subsequent licensing assets.